Skip to main content

Table 1 Laboratory investigation in Case 1

From: Two cases of unresectable hepatocellular carcinoma treated via atezolizumab and bevacizumab combination therapy

Laboratory examination

Complete blood cell count

γGTP

1518

U/L

Viral markers

WBC

4350

u/L

ChE

319

U/L

HBs antigen

(–)

RBC

448

104 u/L

Na

140

mEg/L

HCV antibody

(–)

Hg

15

g/dL

K

4.3

mEg/L

Liver function

Ht

46.2

%

Cl

104

mEg/L

ICG-R

21.3%

Plt

15.5

104 u/L

TP

7.2

g/dL

Child–Pugh score

5

Blood coagulation test

Alb

4.2

g/dL

Child–Pugh grade

A

PT (%)

84.6

%

BUN

13.1

mg/dL

ALBI score

-2.19

PT-INR

1.11

 

Cr

0.76

mg/dL

mALBI grade

2b

Blood chemistry

CRP

0.24

mg/dL

  

T-Bil

1.7

mg/dL

HbA1c

6

%

  

AST

75

U/L

Tumor markers

  

ALT

51

U/L

AFP

160.6

ng/mL

  

LDH

259

U/L

DCP

67,200

mAU/mL

  

ALP

466

U/L

     
  1. γGTP: γ-glutamil transpeptidase, AFP: alpha-fetoprotein, Alb: albumin, ALBI: albumin–bilirubin, ALP: alkaline phosphatase, ALT: alanine aminotransferase, AST: aspatate aminotransferase, BUN: blood–urea–nitrogen, ChE: cholinesterase, Cr: creatinine, CRP: C-reactive protein, DCP: des-gamma carboxyprothrombin, Hb: hemoglobin, HbA1c: hemoglobin A1c, HBs antigen: hepatitis B surface antigen, HCV antibody: hepatitis C virus antibody, Ht: hematocrit, ICG-R: indocyanine green retention, LHD: lactate dehydrogenase, Plt: platelets, PT: prothrombin time, PT-INR: international normalized ratio of prothrombin time, RBC: red bllod cells, T-Bil: total bilirubin, TP: total protein, WBC: white blood cells